Tesofensine
NS2330 · Tesomet (with metformin)
Popular for:Weight loss, triple monoamine reuptake inhibitor, appetite suppression
13
Registered Trials
11
Trial Publications
51
PubMed References
Phase II
Evidence Level
Overview
Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed by NeuroSearch for Parkinson's disease and Alzheimer's. The short version: people usually care about it for weight loss, triple monoamine reuptake inhibitor, appetite suppression, but the strength of the evidence depends heavily on indication and study type.
Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed by NeuroSearch for Parkinson's disease and Alzheimer's. During neurological trials, researchers noticed significant weight loss as a side effect, pivoting the drug toward obesity treatment.
Phase II trials showed remarkable results: up to 12.8% body weight loss over 6 months at the 1.0 mg dose — more than double most approved obesity drugs at the time. It works through a completely different mechanism than GLP-1 agonists, reducing appetite and increasing satiety through triple monoamine reuptake inhibition rather than gut hormone signaling.
Research Snapshot
What the evidence says
Phase IITesofensine currently shows 13 registered trials from ClinicalTrials.gov, 11 PubMed trial publications (11 RCT-tagged), and 51 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 13 registered trials are tracked from ClinicalTrials.gov intervention records.
- 11 PubMed clinical-trial publications are indexed.
- 11 PubMed randomized controlled trial publications are indexed.
- 51 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Tesofensine inhibits the reuptake of serotonin, norepinephrine, and dopamine — the three major monoamine neurotransmitters involved in appetite regulation and reward.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
13
Registered Trials
11
Trial Publications
11
RCT Publications
51
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
13
Registered trials
11
Trial publications
11
RCT publications
51
PubMed references
17
Reviews
1
Meta-analyses
Registered trials source
Jun 1, 2026
Tesofensine
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceInvestigational — Phase III (Saniona). Tesomet (combo with metformin) in trials for Prader-Willi syndrome and hypothalamic obesity. Not yet FDA-approved. Cardiovascular safety is the key regulatory hurdle.
Key PubMed References
51 PubMed references · showing top 25 by relevance
View all on PubMedStructural basis for pharmacotherapeutic action of triple reuptake inhibitors.
Li Y, Meng Y, Li N, et al. · Nature communications · 2025
PMID: 41392177Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
Perez CI, Luis-Islas J, Lopez A, et al. · PloS one · 2024
PMID: 38656972New and emerging drug molecules against obesity.
George M, Rajaram M, Shanmugam E · Journal of cardiovascular pharmacology and therapeutics · 2014
PMID: 24064009Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.
Bentzen BH, Grunnet M, Hyveled-Nielsen L, et al. · Obesity (Silver Spring, Md.) · 2013
PMID: 23784901Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Lancet (London, England) · 2013
PMID: 23561987Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for Tesofensine yet.
Side Effects & Safety
- Increased heart rate (5-8 bpm in trials) - Dry mouth - Insomnia - Constipation - Potential for cardiovascular effects (main regulatory concern) - Not a benign compound — CNS-active, affects multiple neurotransmitter systems
Known Interactions
No curated interaction entry is live for Tesofensine yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.